The Philly-based biotech company will begin human testing of EBT-101, a CRISPR-based gene editing construct developed at Temple’s Lewis Katz School of Medicine. According to Excision’s CEO, Daniel ...
Excision Biotherapeutics Inc.’s CEO is specific when he talks about his company’s therapies and what they may achieve: a functional cure. “When you treat someone and they become cancer free, you can’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback